Press Room


    Press Release - July 30, 2007

    Sernova Files Worldwide Patent Application for Innovative Component of Diabetes

    Kelowna, British Columbia -- July 30, 2007 - Sernova Corp. (TSX-V: SVA), a company focused on a novel treatment for insulin-dependent diabetes using its Sertolin cell technology, is pleased to announce it has filed a patent application for the therapeutic use of adult Sertoli cells. Compared to the standard juvenile cells, adult Sertoli cells have enhanced protective properties that are particularly effective at protecting co- transplanted cells from being destroyed by the body's immune system.

    Sernova has demonstrated that adult Sertoli cells protect insulin-producing islet cells in animal xenotransplants (pig cells implanted into rats), whereas xenotransplants using only islets are destroyed by the immune system within 7 days. Using the Company's Sertolin technology containing adult Sertoli cells, implants have been shown to produce insulin and decrease insulin-dependence for up to 100 days in diabetic rats.

    The patent application complements Sernova's existing portfolio of over 20 patents and several additional patent applications related to the use of Sertoli cells for therapeutic purposes and gene therapy. The application was filed under the Patent Cooperation Treaty (PCT) and extends Sernova's previously filed U.S. provisional application to most countries, including all important industrialized markets.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: TEL: (888) 318-7062 Phil Morehouse FAX: (250) 868-8493 Sernova Corp.



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News